CardioHub - Cardio Town Hall: Amyloidosis Series

CardioHub: Town Hall Series

HFSA’s Cardio Town Hall program delivers timely, expert-led discussions on key cardiovascular topics in a convenient, interactive format. Each 30-minute live seminar features Q&A with leading clinicians, recordings, and downloadable resources available for OnDemand learning. This series is designed to support diverse learning styles and provide practical insights for clinicians specializing in heart failure care.

Amyloidosis (am-uh-loi-DO-sis) is a complex disease associated with abnormal protein accumulations in the heart, kidneys, liver, spleen, nervous system, and digestive tract. Learn more about this complex and serious condition.

This series focuses on Amyloidosis and provides updates on:

What are the New Therapeutic Options? Lessons Learned from ACC
Redefining Care and Expectations for Today's Patients -- Earlier Diagnosis and Optimized Management
Clinical Impact of ATTR Treatment (Beyond Hard Outcomes): Cardiac Remodeling, Function, and Quality of Life
Evolving Guidelines/Advances in Standards of Care

Target Audience:

This activity is intended for cardiologists, interventional cardiologists, primary care physicians, cardiac surgeons, internists, nurse practitioners, physician assistants, nurses, pharmacists, and other health care providers who care for patients with heart failure.

Cardio Town Hall: Amyloidosis Series

What Are the New Therapeutic Options? Lessons Learned from ACC. Therapies for transthyretin (ATTR-CM) and immunoglobulin light chain (AL-CM) cardiac amyloidosis are advancing rapidly. What new Amyloidosis therapeutic options were discussed at ACC.25? Learn more as leading clinicians review the latest clinical trial data and emerging strategies from the meeting. Download What Are the New Therapeutic Options Lessons Learned from ACC - Key Takeaways. Watch now!

Redefining Care and Expectations for Today's Patients - Earlier Diagnosis and Optimized Management. Amyloidosis can be elusive - but with rapidly emerging diagnostic tools and therapies, clinical practice is changing. Join us for our newest CardioHub program. HFSA faculty and expert clinicians will share practical strategies, real-world insights, and patient-centered approaches to optimize care delivery and outcomes, while also providing a 30-minute Q&A session. Watch now!

Clinical Impact of ATTR Treatment: Cardiac Remodeling, Function, and Quality of Life. Coming Soon!
Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) negatively impacts cardiac function, overall health, and quality of life (QOL). The gradual buildup of amyloid fibrils in ATTR-CM results in cardiac remodeling, affects cardiac function, and adversely impacts patients' quality of life. Join HFSA's faculty in this Cardio Town Hall to explore how existing treatments can positively influence these areas and enhance patient outcomes.

Evolving Guidelines/Advances in Standards of Care. Coming Soon!

Subscribe to the HFSA YouTube Channel